Skip to main content

Table 2 Population-wise and subgroup analyses using different genetic models for CYP17, ACE, and VDR polymorphisms

From: Systematic review and meta-analysis of candidate gene association studies of benign prostate hyperplasia

Gene polymorphisms

Population

Dominant model

Recessive model

OR (95% CI)

I2

P value

OR (95% CI)

I2

P value

CYP17 (rs743572)

Overall

0.96 (0.87–1.06)

0%

0.07

0.82 (0.60–1.13)

60.2%

0.005

Asian

0.96 (0.83–1.11)

8%

0.36

0.72 (0.43–1.33)

76.5%

0.0001

Caucasian

0.96 (0.83–1.12)

0%

0.72

0.93 (0.74–1.17)

0%

0.4

ACE (I/D)

Overall

1.00 (0.75–1.35)

28.5%

0.24

1.67 (1.03–2.73)

26.2%

0.25

Asian

0.98 (0.76–1.26)

0%

0.72

1.42 (0.99–2.03)

0%

0.53

Caucasian

1.56 (0.38–6.40)

75.3%

0.04

6.18 (1.38–27.68)

0%

0.73

VDR (fok1)

Overall

0.90 (0.78–1.04)

5.8%

0.37

0.71 (0.54–1.07)

27.7%

0.22

Asian

0.91 (0.76–1.10)

36.7%

0.19

0.69 (0.47–1.03)

40.8%

0.16

Caucasian

0.83 (0.56–1.24)

0%

0.52

1.21 (0.50–2.95)

0%

0.35

VDR (bsm1)

Overall

1.05 (0.80–1.39)

35.6%

0.18

1.34 (0.90–1.99)

0%

0.85

Asian

1.18 (0.73–1.89)

60.8%

0.07

1.29 (0.79–2.19)

0%

0.59

Caucasian

0.91 (0.63–1.29)

0%

0.78

1.40 (0.77–2.53)

0%

0.53

VDR (apaI)

Overall

1.07 (0.77–1.51)

64.9%

0.02

1.23 (0.57–2.64)

77.2%

0.002

Asian

1.17 (0.73–1.89)

76.3%

0.001

1.62 (0.56–4.65)

83.5%

0.002

Caucasian

0.92 (0.50–1.67)

56%

0.13

0.80 (0.40–1.60)

0%

0.43

VDR (TaqI)

Overall

1.16 (0.95–1.42)

8%

0.41

1.36 (0.91–2.02)

0%

0.6

Asian

1.45 (0.86–2.45)

39.5%

0.19

2.34 (0.74–7.33)

0%

0.85

Caucasian

0.98 (0.72–1.32)

0%

0.82

0.92(0.52–1.62)

0%

0.74

  1. Abbreviations: OR Odds ratio, CI Confidence interval, CYP Cytochrome P450c17alpha, ACE Angiotensin-converting enzyme, VDR Vitamin D receptor